Isotretinoin. How should it be used?
Isotretinoin has been the most effective and long-lasting drug for the treatment of severe acne for more than 30 years and can achieve long-term remission in 70-80 % of patients after a single course. New findings concerning its influence on innate immunity, the modulation of growth factors or the time-dependent regulation of genes of inflammation or matrix metabolism contribute to an improved understanding of the dynamic mode of action of isotretinoin. The new evidence-based European S3-guideline recommends the use of Isotretinoin as a first-line medication for the treatment of severe papulopustular or conglobate acne, especially when prognostically unfavorable factors are present: family history of acne, early onset, marked seborrhea, localization on the trunk, scarring, psychosocial disability or persistent/late-type acne. The correlation of a cumulative dose of > 100-120 mg/kg with a reduced relapse rate can be regarded as established in patients with severe acne forms, whereas in milder, "off-label"-treated acne forms, a good clinical outcome can also be achieved with lower cumulative doses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - 64(2013), 4 vom: 21. Apr., Seite 263-8 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Isotretinoin. Wie behandelt man richtig? |
|---|
| Beteiligte Personen: |
Thielitz, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dermatologic Agents |
|---|
| Anmerkungen: |
Date Completed 07.11.2013 Date Revised 21.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00105-012-2467-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM226001822 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM226001822 | ||
| 003 | DE-627 | ||
| 005 | 20231224070435.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00105-012-2467-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0753.xml |
| 035 | |a (DE-627)NLM226001822 | ||
| 035 | |a (NLM)23515581 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Thielitz, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Isotretinoin. How should it be used? |
| 246 | 3 | 3 | |a Isotretinoin. Wie behandelt man richtig? |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.11.2013 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Isotretinoin has been the most effective and long-lasting drug for the treatment of severe acne for more than 30 years and can achieve long-term remission in 70-80 % of patients after a single course. New findings concerning its influence on innate immunity, the modulation of growth factors or the time-dependent regulation of genes of inflammation or matrix metabolism contribute to an improved understanding of the dynamic mode of action of isotretinoin. The new evidence-based European S3-guideline recommends the use of Isotretinoin as a first-line medication for the treatment of severe papulopustular or conglobate acne, especially when prognostically unfavorable factors are present: family history of acne, early onset, marked seborrhea, localization on the trunk, scarring, psychosocial disability or persistent/late-type acne. The correlation of a cumulative dose of > 100-120 mg/kg with a reduced relapse rate can be regarded as established in patients with severe acne forms, whereas in milder, "off-label"-treated acne forms, a good clinical outcome can also be achieved with lower cumulative doses | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Dermatologic Agents |2 NLM | |
| 650 | 7 | |a Isotretinoin |2 NLM | |
| 650 | 7 | |a EH28UP18IF |2 NLM | |
| 700 | 1 | |a Gollnick, H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete |d 1952 |g 64(2013), 4 vom: 21. Apr., Seite 263-8 |w (DE-627)NLM000041157 |x 1432-1173 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2013 |g number:4 |g day:21 |g month:04 |g pages:263-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00105-012-2467-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2013 |e 4 |b 21 |c 04 |h 263-8 | ||